InterCure (dba Canndoc) (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated "seed-to-sale" model to lead the fastest growing cannabis global market outside of North America.
For more information, visit: http://www.intercure.co.
Company Details
- Employees
- 23
- Founded
- -
- Address
- Herzliya, Il
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://www.intercure.co
- HQ
- Herzliya
Intercure Questions
Intercure's website is http://www.intercure.co
Intercure's LinkedIn profile is https://il.linkedin.com/company/inter-cure
Intercure has
23 employees.
View email and phone details for 23
employees at Intercure.
Intercure's industry is
Pharmaceutical Manufacturing
Intercure's top competitors are
Qunubus Pharmaceutical,
Can4med,
Seach Medical Group,
Cannaflos Genetics S.l.,
Bol Pharma,
Tikun Olam Cannbit Pharmaceuticals Ltd.,
Canndoc,
Panaxia Pharmaceutical Industries,
Cannbit,
Cannassure.
Intercure's categories are Pharmaceutical Manufacturing
Intercure's founding year is 2008
